The pXg (proteomics X genomics) pipeline is a bioinformatics tool for identifying noncanonical MHC-I-associated peptides (ncMAPs) using de novo peptide sequencing and RNA-Seq data . While not an antibody itself, pXg integrates proteomic and genomic features to improve the identification of immunopeptides, including those potentially targeted by therapeutic antibodies.
Key Features of pXg:
Combines de novo peptide sequencing with RNA-Seq reads to expand search space beyond reference databases .
Uses machine learning (Percolator) with proteogenomic features (RNA-Seq abundance, sequencing quality) to refine peptide-spectrum matches .
Identifies viral proteins and antibody-derived peptides, such as complementarity determining region 3 (CDR3) .
| Identified Peptides | Canonical MAPs | Noncanonical MAPs |
|---|---|---|
| Total Identified (10 samples) | 24,449 | 956 |
| Novel Discoveries | 1,611 | 387 |
This pipeline enhances the discovery of immunotherapeutic targets but does not directly involve a "PXG antibody" .
CLO/PXG (caleosin/peroxygenase) proteins are calcium-binding enzymes involved in lipid metabolism and stress responses . Antibodies targeting these proteins could be termed "PXG antibodies," though none are explicitly described in the reviewed literature.
Functional Properties of CLO/PXG Proteins:
Structure: Contain EF-hand calcium-binding motifs, lipid-binding domains, and heme-coordinating histidine residues .
Activity: Exhibit peroxygenase functions in oxylipin metabolism (epoxidation, hydroxylation) .
Localization: Associate with lipid droplets and bilayer membranes .
| Process | Role of CLO/PXG Proteins |
|---|---|
| Seed Germination | Lipid droplet mobilization |
| Drought Stress | Epoxy fatty acid synthesis |
| Pathogen Response | Oxylipin signaling |
In ophthalmology, PXG refers to pseudoexfoliation glaucoma. A study analyzed anti-phospholipid antibody (APLA) levels in PXG patients post-trabeculectomy :
| Parameter | PXG Patients (n=14) | POAG Patients (n=14) |
|---|---|---|
| Pre-Op IOP (mmHg) | 30.1 | 29.1 |
| Post-Op IOP (mmHg) | 15.0 | 13.1 |
| Post-Op CRA PSV (cm/s) | 9.79 | 10.11 |
Patients with elevated APLAs showed reduced intraocular pressure (IOP), though no direct "PXG antibody" was identified .
While unrelated to "PXG," a clinical trial combined the GVAX vaccine, nivolumab (anti-PD-1), and urelemab (anti-CD137 agonist antibody) to boost T-cell responses in pancreatic cancer . This highlights the broader role of antibodies in immunotherapy but does not involve PXG-specific antibodies.
Though not PXG-specific, polyreactive antibodies (e.g., IgM, IgA) bind structurally diverse antigens with low affinity :
| Property | Polyreactive Antibodies | Monoreactive Antibodies |
|---|---|---|
| Antigen Specificity | Diverse (DNA, proteins) | Single cognate antigen |
| Affinity (Kd) | 10⁻⁴–10⁻⁷ | 10⁻⁷–10⁻¹¹ |
| Somatic Mutation | Rare | Common |
PAX2 is a transcription factor that plays a critical role in stem cell survival and lineage commitment during embryonic development. It functions as a key regulator in the formation of several organ systems, particularly in kidney development and the central nervous system. In research contexts, PAX2 is frequently studied as a marker for developmental processes, stem cell differentiation, and certain pathological conditions . PAX2 is also expressed in various carcinomas where it appears to mediate anti-apoptotic processes, making it relevant for cancer research as well . For developmental biologists, PAX2 antibodies are essential tools for tracking the expression of this protein during critical developmental windows and for identifying specific cell populations during organogenesis.
PAX2 antibody has been validated for multiple sample types in research applications:
| Sample Type | Validated Applications | Species Compatibility |
|---|---|---|
| Tissue sections | IHC, IF | Human, Mouse, Rat |
| Cell cultures | ICC/IF | Human embryonic stem cells |
| Tissue lysates | Western blot | Mouse kidney |
| Embryonic tissues | IHC, IF | Mouse, Rat |
| Neural tissues | IHC | Rat spinal dorsal horn |
Research data demonstrates successful application of PAX2 antibody in paraffin-embedded kidney sections, embryonic stem cells differentiated into early otic lineage, and spinal cord tissues . When working with novel sample types, researchers should conduct preliminary validation experiments with appropriate positive controls.
While the product is labeled as Human PAX2 Antibody, experimental validation has confirmed cross-reactivity with multiple species. The antibody has been successfully used to detect PAX2 in human, mouse, and rat samples . Specifically, Western blot experiments have validated reactivity with mouse fetal kidney lysates, immunohistochemistry has confirmed detection in human kidney sections, and immunofluorescence studies have demonstrated effective labeling in rat spinal dorsal horn tissue . This broad cross-species reactivity makes the antibody particularly valuable for comparative studies across different model organisms.
For optimal PAX2 detection in paraffin-embedded tissues, the following protocol has been validated:
Tissue preparation: Process tissues using standard fixation (10% neutral buffered formalin) and paraffin embedding
Sectioning: Cut sections at 5-7 μm thickness
Antigen retrieval: Perform heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (pH 8.0-9.0)
Primary antibody: Apply PAX2 Antibody at 1 μg/mL concentration
Incubation: Incubate for 1 hour at room temperature
Detection system: Use Anti-Goat IgG VisUCyte HRP Polymer Antibody
Visualization: Develop with DAB (brown) and counterstain with hematoxylin (blue)
This protocol has been specifically validated for human kidney samples, where PAX2 shows nuclear localization in convoluted tubules . Researchers should note that optimization may be required for different tissue types, particularly those with lower PAX2 expression levels.
PAX2 antibody has been effectively used to identify specific inhibitory interneuron populations in the spinal dorsal horn. Research protocols have demonstrated:
Co-localization studies: PAX2 (detected with AF3364 antibody) can be used alongside other markers like prodynorphin (PDYN) to characterize specific neuronal subtypes
Quantification methodology: For accurate quantification, PAX2+ neurons can be counted in defined anatomical regions (e.g., superficial laminae) on both ipsilateral and contralateral sides
Statistical analysis: Unpaired t-tests have been used to compare PAX2+ neuron numbers between experimental conditions (e.g., after DTX vs. PBS injection)
In published studies, PAX2 antibody has successfully identified a subset of inhibitory neurons when combined with AAV-PdynP-tdT labeling, with approximately 70% of labeled neurons co-expressing PAX2 . This approach allows researchers to target specific neuronal populations for functional studies in pain and sensory processing research.
When using PAX2 antibody in multiplex immunofluorescence studies, researchers should consider:
Antibody compatibility: Carefully select primary antibodies raised in different host species to avoid cross-reactivity
Sequential staining protocol:
PAX2 detection: Use Goat Anti-Human PAX2 at 10 μg/mL for 3 hours at room temperature
Detection with species-specific secondary antibody (e.g., NorthernLights 557-conjugated Anti-Goat IgG)
Follow with additional primary antibodies (e.g., VGLUT2, PDYN) raised in different species
Controls: Include single-stained controls to confirm specificity and rule out cross-reactivity
Image acquisition: Use sequential scanning to minimize spectral overlap
Published studies have successfully combined PAX2 immunolabeling with markers such as VGLUT2, PDYN, and tdTomato reporter expression in neuronal populations . Quantification of co-expression can be performed by counting double-positive cells as a percentage of total marker-positive cells.
PAX2 antibody serves as a valuable tool in stem cell research for:
Lineage tracing: Tracking cells committed to specific developmental pathways
Differentiation confirmation: Validating successful differentiation of stem cells into particular cell types
Temporal expression analysis: Monitoring PAX2 expression changes during differentiation processes
Experimental data shows that PAX2 antibody has been successfully used to detect PAX2 in BG01V human embryonic stem cells differentiated into early otic lineage . For such applications, immunofluorescence protocol optimization typically involves:
Fixation with 4% paraformaldehyde for 15-20 minutes
Permeabilization with 0.1-0.3% Triton X-100
Blocking with 5-10% normal serum
Primary antibody incubation at 10 μg/mL for 3 hours at room temperature
Detection with fluorophore-conjugated secondary antibodies
Researchers should monitor nuclear localization of PAX2 staining as a critical quality control parameter.
When utilizing PAX2 antibody for Western blot analysis, researchers should address these common challenges:
Optimizing protein extraction: Nuclear proteins like PAX2 require effective nuclear extraction methods
Ensuring appropriate sample preparation:
Use RIPA or NP-40 based lysis buffers with protease inhibitors
Include DNase treatment to reduce sample viscosity
Heat samples at 95°C for 5 minutes in reducing buffer
Gel selection and transfer conditions:
Use 10-12% SDS-PAGE gels for optimal separation
Transfer to PVDF membrane at 100V for 60-90 minutes
Detection parameters:
Western blot analysis with PAX2 antibody typically reveals a specific band at approximately 47 kDa, as demonstrated in mouse fetal kidney lysate samples . Non-specific bands may appear if washing steps are inadequate or if antibody concentration is too high.
For rigorous quantification of PAX2 expression in immunohistochemistry studies, researchers should follow these methodological approaches:
Sampling strategy:
Examine multiple non-overlapping fields per section
Analyze multiple sections per sample
Include biological replicates (n ≥ 3-6 animals/patients)
Quantification methods:
Count total PAX2+ cells in defined anatomical regions
Measure staining intensity using calibrated image analysis software
Calculate percentage of PAX2+ cells relative to total cell count
Statistical analysis:
Published studies have successfully quantified PAX2+ neurons in the superficial laminae of rat spinal dorsal horn, demonstrating significant differences between ipsilateral and contralateral sides following experimental manipulation (p < 0.0001, Unpaired t-test) . This approach provides robust quantitative data for comparative studies.
PAX2 antibody has proven valuable in neurological research focusing on inhibitory interneurons in pain circuits:
Identification of neuronal subpopulations: PAX2 serves as a marker for inhibitory interneurons in the spinal dorsal horn
Functional characterization:
Manipulation studies:
Research has demonstrated that ablation of specific PAX2+ neuronal populations in the spinal dorsal horn affects sensory processing, providing insights into the neural circuits involved in pain perception and mechanical allodynia .
To ensure experimental rigor when using PAX2 antibody, researchers should include these essential controls:
| Control Type | Purpose | Implementation |
|---|---|---|
| Positive tissue control | Confirm antibody reactivity | Include known PAX2-expressing tissue (e.g., kidney) |
| Negative tissue control | Assess background | Include tissue known to lack PAX2 expression |
| No primary antibody | Evaluate secondary antibody specificity | Omit primary antibody but include all other steps |
| Isotype control | Assess non-specific binding | Use non-immune goat IgG at equivalent concentration |
| Peptide competition | Confirm epitope specificity | Pre-incubate antibody with immunizing peptide |
| siRNA/knockout validation | Ultimate specificity control | Compare staining in tissues with PAX2 knockdown |
Additionally, when conducting co-expression studies, single-label controls should be included to assess bleed-through in multichannel imaging . These comprehensive controls are essential for publication-quality research and ensure accurate interpretation of PAX2 expression patterns.
PAX2 expression has been identified in various carcinomas, making PAX2 antibody a valuable tool in cancer research:
Expression profiling:
Characterize PAX2 expression patterns in different tumor types
Correlate expression with clinical parameters and outcomes
Mechanistic studies:
Investigate PAX2's role in anti-apoptotic mechanisms
Examine PAX2's influence on cancer cell proliferation and survival
Diagnostic applications:
Evaluate PAX2 as a potential diagnostic marker
Determine if PAX2 expression can distinguish tumor subtypes
Methodological approach:
For cancer studies, researchers should consider combining PAX2 immunostaining with other diagnostic markers to improve specificity and investigate potential correlations with known prognostic indicators.
When encountering weak or absent PAX2 staining, researchers should systematically evaluate:
Antigen retrieval optimization:
Test different antigen retrieval buffers (citrate pH 6.0 vs. EDTA pH 9.0)
Extend retrieval time (10-30 minutes)
Ensure complete deparaffinization
Antibody conditions:
Increase primary antibody concentration (up to 10 μg/mL)
Extend incubation time (overnight at 4°C)
Test alternative secondary detection systems
Tissue quality assessment:
Evaluate fixation conditions (overfixation can mask epitopes)
Confirm tissue viability with control antibodies
Check time between tissue collection and fixation
Signal amplification:
Published protocols have successfully detected PAX2 in human kidney using 1 μg/mL antibody concentration with heat-induced epitope retrieval and HRP polymer detection system . These parameters can serve as a starting point for optimization with other tissue types.